Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

An update from Moderna ( ($MRNA) ) is now available. In a January 5, 2026 letter to shareholders, Moderna reviewed a challenging 2025 operating ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Kostaive (zapomeran) mRNA COVID-19 ...

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m (1) TP).

Editorial: Over the holiday period, the Guardian leader column is looking ahead at the themes of 2026. Today we examine how the White House’s war on vaccines has left the future of a key technology un ...

Moderna (MRNA) has reiterated its target of up to 10% revenue growth in 2026, supported by a strategy to build a large ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This milestone ...

If licensed and in the event of an influenza pandemic, Moderna will allocate 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable ...

Bayer's agrochemicals unit Monsanto has filed lawsuits in the US against the manufacturers of mRNA-based COVID-19 vaccines, ...